Welcome to our dedicated page for ImmunityBio SEC filings (Ticker: IBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ImmunityBio, Inc. filings document the formal reporting record for a commercial-stage immunotherapy company with Nasdaq-listed common stock. Form 8-K reports furnish operating results, ANKTIVA product revenue updates, regulatory authorizations for ANKTIVA with BCG in NMIBC, FDA promotional-compliance correspondence, and material agreements including revenue interest purchase agreement amendments and convertible promissory note amendments.
Proxy materials cover board elections, executive compensation, equity awards, pay-versus-performance data, and shareholder voting matters. The filings also describe capital structure and financing obligations, related-party arrangements, and risk factors tied to clinical development, regulatory review, manufacturing and supply, commercialization, reimbursement, competition, and market acceptance.
ImmunityBio director and major holder Patrick Soon-Shiong reported vesting of restricted stock units and related share movements. On February 22, 2026, 114,329 restricted stock units were exercised into an equal number of common shares at $0.00 per share. To cover tax obligations, 58,170 common shares were disposed of at $8.70 per share through share withholding, leaving 29,757,911 common shares held directly after these transactions. Additional large blocks of ImmunityBio common stock are reported as held indirectly through affiliated entities such as Nant Capital, Cambridge Equities, NantBio, California Capital Equity, the Chan Soon-Shiong Family Foundation, NantWorks, NantMobile, and NantCancerStemCell, over which the reporting person may be deemed to have voting and dispositive power as described in the footnotes.
ImmunityBio, Inc. Chief Accounting Officer Regan J. Lauer reported vesting of 4,065 restricted stock units (RSUs) on February 22, 2026. Each RSU converts into one share of common stock, so 4,065 shares were acquired at a stated price of $0.00 per share.
To satisfy tax obligations from this vesting, 1,673 common shares were disposed of at $8.70 per share through share withholding, rather than an open-market sale. After these transactions, Lauer directly owns 115,875 shares of ImmunityBio common stock.
ImmunityBio, Inc. director, CEO and President Richard Adcock reported equity award activity involving restricted stock units (RSUs) and common stock. On February 22, 2026, 152,439 RSUs were exercised or converted into 152,439 shares of common stock at a price of $0.00 per share, reflecting vesting of a prior RSU grant.
In a related tax-withholding transaction, 77,560 shares of common stock were disposed of at $8.70 per share to cover tax obligations associated with the RSU vesting, rather than an open-market sale. Following these transactions, Adcock directly held 560,344 shares of ImmunityBio common stock. Footnotes explain that each RSU represents a right to receive one share of common stock and outline a three-year vesting schedule that began on February 22, 2024, conditioned on continued service.
ImmunityBio director Barry J. Simon reported a mix of stock sales and equity awards for ImmunityBio, Inc. common stock. He sold 165,000 shares on February 23, 2026 in open-market transactions at a weighted average price of $10.2491 per share under a Rule 10b5-1 trading plan, and sold another 10,000 shares on February 20, 2026 at $9.25 per share. On February 22, 2026, restricted stock units representing 15,243 shares vested and were converted into common stock at no cost, with 6,026 shares withheld at $8.70 per share to cover taxes. After these transactions, he directly owned 2,925,821 shares of ImmunityBio common stock.
ImmunityBio, Inc. outlines how it is transitioning into a commercial-stage immunotherapy company built around its IL-15 receptor superagonist ANKTIVA. Net product revenue reached approximately $113 million in 2025, with about 700% year-over-year growth and Q4 2025 revenue of $38.3 million, supported by lives covered exceeding 240 million in the U.S.
ANKTIVA with BCG is approved for BCG-unresponsive NMIBC CIS in the U.S., UK and Saudi Arabia and has conditional EU authorization, while Saudi Arabia granted conditional approval with checkpoint inhibitors for metastatic NSCLC. The company is running an extensive pipeline of trials across bladder, lung, pancreatic, brain and hematologic cancers, as well as infectious diseases, and has received FDA RMAT designation and multiple expanded access authorizations tied to lymphopenia reversal.
ImmunityBio, Inc. notice: a Form 144 discloses a proposed sale of 25,000 common shares on 02/23/2026 related to an exercise of stock options. The filing records prior 10b5-1 sales by Christobel Selecky of 25,000 shares on 01/20/2026 for $187,650 and 50,000 shares on 01/16/2026 for $250,000.
ImmunityBio reported full-year 2025 results highlighting explosive ANKTIVA growth alongside continued losses. Net product revenue from ANKTIVA reached $113 million, an approximately 700% year-over-year increase, with Q4 2025 net product revenue of $38.3 million and unit sales up about 750% versus 2024.
Regulatory approvals now cover BCG-unresponsive bladder cancer across four jurisdictions and 33 countries, and Saudi Arabia granted conditional accelerated approval for metastatic non-small cell lung cancer, with launch planned within 60 days of approval. Despite this momentum, the company posted a 2025 net loss attributable to common stockholders of $351.4 million, improved from $413.6 million in 2024, and ended the year with $242.8 million in cash, cash equivalents, and marketable securities against total liabilities of $1.0 billion.
ImmunityBio reported that the European Commission has granted conditional marketing authorization for ANKTIVA (nogapendekin alfa inbakicept) plus BCG to treat adults with BCG‑unresponsive non‑muscle invasive bladder cancer carcinoma in situ, with or without papillary tumors.
This decision makes ANKTIVA the first immunotherapy authorized in Europe for this high‑risk bladder cancer setting and extends availability across all 27 EU member states plus Iceland, Norway, and Liechtenstein, bringing total country coverage to 33. Approval is based on the QUILT‑3.032 trial, which showed a 71% complete response rate, a median complete response duration of 26.6 months, and cystectomy‑free survival among responders of 96% at 12 months and 84% at 36 months.
The authorization is conditional and requires ImmunityBio to submit long‑term safety and efficacy data and renew the authorization annually, while the company pursues pricing, reimbursement, and patient access across Europe.
ImmunityBio, Inc. insider activity: Patrick Soon-Shiong and affiliated entities reported equity award vesting and related share movements. On February 10, 2026, 274,122 restricted stock units were converted into an equal number of ImmunityBio common shares at an exercise price of $0.00. To cover tax obligations on this vesting, 118,560 common shares were withheld at a price of $6.93 per share. Following these transactions, Soon-Shiong directly held 29,701,752 common shares. The filing also lists very large indirect holdings through entities such as Nant Capital, Cambridge Equities, NantBio, California Capital Equity, the Chan Soon-Shiong Family Foundation, NantWorks, NantMobile and NantCancerStemCell, over which he is described as having varying degrees of voting and dispositive power.
ImmunityBio, Inc. Chief Financial Officer David C. Sachs reported RSU vesting and related share withholding. On February 10, 2026, 82,236 restricted stock units converted into 82,236 shares of common stock at an exercise price of $0, increasing his directly held common stock to 322,818 shares.
On the same date, 42,643 common shares were disposed of at $6.93 per share to cover tax obligations tied to the RSU vesting, leaving him with 280,175 common shares held directly after these transactions. Following the vesting, he also held 164,474 RSUs directly.